Literature DB >> 16086583

Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques.

Leticia Miravalle1, Miguel Calero, Masaki Takao, Alex E Roher, Bernardino Ghetti, Ruben Vidal.   

Abstract

Cotton wool plaques (CWPs) are round lesions that lack a central amyloid core. CWPs have been observed in individuals affected by early-onset familial Alzheimer disease (FAD) associated with mutations in the presenilin 1 (PSEN1) gene. Here we present the characterization of the amyloid-beta (Abeta) peptides deposited in the brain of an individual affected by FAD carrying the novel missense (V261I) mutation in the PSEN1 gene. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry was used to determine the Abeta peptide species present in the cerebral and cerebellar cortices, in leptomeningeal vessels, and in CWPs isolated by laser microdissection (LMD). Our results indicate that amino-terminally truncated Abeta peptide species ending at residues 42 and 43 are the main Abeta peptides deposited in brain parenchyma and LMD-CWPs in association with the PSEN1 V261I mutation. Full-length Abeta1-42 and Abeta1-43 peptide species were underrepresented. CWPs were not found to be associated with vessels and did not contain Abeta1-40 peptides, the main component of the vascular deposits. Although Abeta deposits were present mostly in the form of CWPs in the cerebral cortex and as diffuse deposits in the cerebellar cortex, a similar array of amino-terminally truncated Abeta peptide species was seen in both cases. The biochemical data support the concept that parenchymal and vascular amyloid deposits are associated with a different array of Abeta peptide species. The generation and parenchymal deposition of highly insoluble amino-terminally truncated Abeta peptides may play an important role in the pathogenesis of AD and must be taken into consideration in developing new diagnostic and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086583     DOI: 10.1021/bi0508237

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  56 in total

1.  PYROGLUTAMATE FORMATION AT THE N-TERMINI OF ABRI MOLECULES IN FAMILIAL BRITISH DEMENTIA IS NOT RESTRICTED TO THE CENTRAL NERVOUS SYSTEM.

Authors:  Yasushi Tomidokoro; Akira Tamaoka; Janice L Holton; Tammaryn Lashley; Blas Frangione; Tamas Revesz; Agueda Rostagno; Jorge Ghiso
Journal:  Hirosaki Igaku       Date:  2010-07-08

Review 2.  Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions.

Authors:  Tyler A Kokjohn; Alex E Roher
Journal:  Alzheimers Dement       Date:  2009-07       Impact factor: 21.566

3.  Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Authors:  Alex E Roher; Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Jesse M Hunter; Marwan N Sabbagh; Thomas G Beach
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  Forgetful and robotic: tap on a gene!

Authors:  Lucio Tremolizzo; E Susani; D Binda; F Bertola; C Ferrarese; I Appollonio
Journal:  Neurol Sci       Date:  2015-01-08       Impact factor: 3.307

5.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

6.  Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.

Authors:  Markus Morawski; Maike Hartlage-Rübsamen; Carsten Jäger; Alexander Waniek; Stephan Schilling; Claudia Schwab; Patrick L McGeer; Thomas Arendt; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2010-04-10       Impact factor: 17.088

7.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.

Authors:  An Tanghe; Annelies Termont; Pascal Merchiers; Stephan Schilling; Hans-Ulrich Demuth; Louise Scrocchi; Fred Van Leuven; Gerard Griffioen; Tom Van Dooren
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

Review 8.  Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.

Authors:  Tyler A Kokjohn; Alex E Roher
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

9.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.